[{"internal_id": 68172111, "Award ID": "UH3OD023328", "Award Amount": 18555992.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-29", "CFDA Number": "93.310", "Description": "BREAKING THE CYCLE OF INTERGENERATIONAL DISADVANTAGE: NEURODEVELOPMENT AMONG PUERTO RICAN CHILDREN.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be04d9d3-d584-2183-f93b-e5cb978627ac-C", "generated_internal_id": "ASST_NON_UH3OD023328_7529"}, {"internal_id": 50105697, "Award ID": "U54CA096297", "Award Amount": 26378768.47, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2007-09-24", "CFDA Number": "93.397", "Description": "UPRCCC/MDACC: PARTNERSHIP FOR EXCELLENCE IN CANCER RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_U54CA096297_7529"}, {"internal_id": 49981310, "Award ID": "SC3GM116684", "Award Amount": 526836.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-11", "CFDA Number": "93.859", "Description": "EFFECT OF LOW-INTENSITY VERSUS MODERATE-INTENSITY ENDURANCE EXERCISE ON PHYSICAL FUNCTIONING AMONG BREAST CANCER SURVIVORS: A RANDOMIZED CONTROLLED T", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_SC3GM116684_7529"}, {"internal_id": 49981288, "Award ID": "SC3GM111171", "Award Amount": 452405.81, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-28", "CFDA Number": "93.661", "Description": "SENSITIZATION OF BREAST CANCER AND CANCER STEM CELL TO SYSTEMIC THERAPY BY REISHI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "45b9cacc-2d26-0151-3827-b5e8d6e9303b-C", "generated_internal_id": "ASST_NON_SC3GM111171_7529"}, {"internal_id": 49981159, "Award ID": "SC3GM084824", "Award Amount": 1600899.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-09", "CFDA Number": "93.859", "Description": "MOLECULAR TARGETS OF SOY ISOFLAVONES IN BREAST CANCER PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_SC3GM084824_7529"}, {"internal_id": 49981008, "Award ID": "SC2GM111149", "Award Amount": 521743.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-20", "CFDA Number": "93.859", "Description": "GLIAL UPTAKE OF DOPAMINE AFTER L-DOPA MEDICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "45b9cacc-2d26-0151-3827-b5e8d6e9303b-C", "generated_internal_id": "ASST_NON_SC2GM111149_7529"}, {"internal_id": 49980713, "Award ID": "SC1NS095380", "Award Amount": 1608996.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-22", "CFDA Number": "93.859", "Description": "MITOCHONDRIAL DNA AND APE1 IN HUNTINGTON'S DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_SC1NS095380_7529"}, {"internal_id": 49980664, "Award ID": "SC1GM122691", "Award Amount": 1653905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-07", "CFDA Number": "93.859", "Description": "MICROGLIA FACILITATE GLIOMA PROGRESSION THROUGH THE PYK2 AND FAK SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "45b9cacc-2d26-0151-3827-b5e8d6e9303b-C", "generated_internal_id": "ASST_NON_SC1GM122691_7529"}, {"internal_id": 49980651, "Award ID": "SC1GM113691", "Award Amount": 1829271.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-17", "CFDA Number": "93.663", "Description": "TARGETING MONOCYTE/MACROPHAGE CATHEPSIN B IN HIV-1 NEUROCOGNITIVE DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_SC1GM113691_7529"}, {"internal_id": 49816324, "Award ID": "R43AI134194", "Award Amount": 345652.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-12", "CFDA Number": "93.663", "Description": "LOW COST POINT-OF-CARE TEST FOR CMV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e418305b-e68c-7ec7-c842-f6ba111de04a-C", "generated_internal_id": "ASST_NON_R43AI134194_7529"}, {"internal_id": 49807102, "Award ID": "R25MD010399", "Award Amount": 977214.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-25", "CFDA Number": "93.879", "Description": "INCREASING DIVERSITY IN INTERDISCIPLINARY BD2K (IDI-BD2K)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4b0f7689-aaf8-396f-d4b3-b944796d133f-C", "generated_internal_id": "ASST_NON_R25MD010399_7529"}, {"internal_id": 68565922, "Award ID": "R21HL140268", "Award Amount": 362743.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.663", "Description": "CLINICAL ANALYSIS OF TREM-LIKE TRANSCRIPT-1 IN LARGE COHORTS OF PATIENTS FROM THE NHLBI BIOREPOSITORY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4b0f7689-aaf8-396f-d4b3-b944796d133f-C", "generated_internal_id": "ASST_NON_R21HL140268_7529"}, {"internal_id": 49798703, "Award ID": "R21GM119018", "Award Amount": 674304.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-06", "CFDA Number": "93.663", "Description": "FUNCTIONAL INTERACTION OF GBAS AND SLC41A2 IN DROSOPHILA MODELS FOR UDP_755", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R21GM119018_7529"}, {"internal_id": 49796098, "Award ID": "R21DE027235", "Award Amount": 838427.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-21", "CFDA Number": "93.121", "Description": "DENTAL AND CRANIOFACIAL EFFECTS OF INTRAUTERINE ZIKA VIRUS INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_R21DE027235_7529"}, {"internal_id": 49793986, "Award ID": "R21CA198963", "Award Amount": 485436.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-09", "CFDA Number": "93.663", "Description": "ASSOCIATION OF GUT BACTERIAL GENES AND DIET TO COLORECTAL NEOPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_R21CA198963_7529"}, {"internal_id": 49786387, "Award ID": "R21AG057974", "Award Amount": 630380.81, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-15", "CFDA Number": "93.866", "Description": "BALANCING DEGENERATION AND REGENERATION IN THE ECHINODERM NERVOUS SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4b0f7689-aaf8-396f-d4b3-b944796d133f-C", "generated_internal_id": "ASST_NON_R21AG057974_7529"}, {"internal_id": 49783660, "Award ID": "R15NS095318", "Award Amount": 589036.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-14", "CFDA Number": "93.663", "Description": "SYNAPTIC VESICLE DYNAMICS AT HIPPOCAMPAL SYNAPSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "45b9cacc-2d26-0151-3827-b5e8d6e9303b-C", "generated_internal_id": "ASST_NON_R15NS095318_7529"}, {"internal_id": 49783043, "Award ID": "R15GM124595", "Award Amount": 1089024.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-23", "CFDA Number": "93.859", "Description": "ROADMAP FOR INTESTINAL REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4b0f7689-aaf8-396f-d4b3-b944796d133f-C", "generated_internal_id": "ASST_NON_R15GM124595_7529"}, {"internal_id": 49781994, "Award ID": "R15CA182769", "Award Amount": 505750.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-16", "CFDA Number": "93.663", "Description": "NOVEL THERAPEUTICS TARGETING HER2 POSITIVE BREAST CANCER BRAIN METASTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a95b9572-dc03-ba8d-34a5-edc32a8efc03-C", "generated_internal_id": "ASST_NON_R15CA182769_7529"}, {"internal_id": 49769046, "Award ID": "R01NS099036", "Award Amount": 2588075.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-09", "CFDA Number": "93.853", "Description": "EXOSOME-MEDIATED SOLUBLE INSULIN RECEPTOR SECRETION CORRELATES WITH HAND", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_R01NS099036_7529"}, {"internal_id": 49747041, "Award ID": "R01GM111452", "Award Amount": 1960887.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-28", "CFDA Number": "93.859", "Description": "A NOVEL FORCE SPECTROSCOPY TO STUDY THE RIBOSOME POWER STROKE AND FRAMESHIFTING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a95b9572-dc03-ba8d-34a5-edc32a8efc03-C", "generated_internal_id": "ASST_NON_R01GM111452_7529"}, {"internal_id": 49746947, "Award ID": "R01GM110382", "Award Amount": 1845775.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-10", "CFDA Number": "93.859", "Description": "SELECTIVE NITROGEN ATOM TRANSFER FOR APPLICATIONS IN BIOMEDICAL SCIENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cbfadf27-8176-30f2-9f5f-7e229ff247ef-C", "generated_internal_id": "ASST_NON_R01GM110382_7529"}, {"internal_id": 49714996, "Award ID": "R01AI125434", "Award Amount": 2755725.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.855", "Description": "HYDROGEN SULFIDE AND NRF2 CROSS-TALK IN VIRAL INFECTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b5d65b01-d8ce-624c-a95e-e23d872445a2-C", "generated_internal_id": "ASST_NON_R01AI125434_7529"}, {"internal_id": 68566340, "Award ID": "R00DE024571", "Award Amount": 1053494.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-14", "CFDA Number": "93.121", "Description": "GENETIC AND ENVIRONMENTAL RISKS FOR ORAL CLEFTS IN PUERTO RICAN HISPANICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_R00DE024571_7529"}, {"internal_id": 48915778, "Award ID": "K23DE025313", "Award Amount": 789667.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-13", "CFDA Number": "93.121", "Description": "STUDY OF PATHWAYS IN THE LINK BETWEEN TYPE 2 DIABETES AND PERIODONTITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_K23DE025313_7529"}]